Your browser doesn't support javascript.
loading
Electroconvulsive Therapy Alone for Schizophrenia: A Meta-analysis of Randomized, Single-blind, Controlled Trials [RETRACTED].
Zheng, Wei; Xiang, Ying-Qiang; Ungvari, Gabor S; Ng, Chee H; Chiu, Helen F K; Liu, Zheng-Rong; Cao, Xiao-Lan; Guo, Tong; Wang, Harry H X; Seiner, Stephen J; Xiang, Yu-Tao.
Afiliação
  • Zheng W; From the *Guangzhou Brain Hospital (Guangzhou Huiai Hospital), Affiliated Hospital of Guangzhou Medical University, Guangzhou; †Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China; ‡School of Psychiatry and Clinical Neurosciences, University of Western Australia; §The University of Notre Dame Australia/Marian Centre, Perth; ∥Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia; ¶Department of Psychiatry, Chi
J ECT ; 2016 08 03.
Article em En | MEDLINE | ID: mdl-27227402
ABSTRACT

PURPOSE:

Electroconvulsive therapy (ECT) is a common treatment in practice for schizophrenia in most developing countries. This is a meta-analysis of the efficacy and safety of ECT alone versus antipsychotic (AP) monotherapy for schizophrenia using randomized, single-blind, controlled trial (RCT) data.

METHODS:

Two assessors independently extracted data. Standardized and weighted mean difference (SMD/WMD), odds ratios (ORs) ± 95% confidence intervals (CIs), and number needed to harm (NNH) were calculated by Review Manager Version 5.3 and the Comprehensive Meta-Analysis Version 2 software.

RESULTS:

Five RCTs (n = 365; age, 34.1 ± 4.7 years; percentage of male, 52.8 ± 9.5; range on the Jaded scale, 2-3) were identified and analyzed. Electroconvulsive therapy alone was superior to AP monotherapy with chlorpromazine, haloperidol, paliperidone, clozapine, and risperidone, respectively, regarding symptomatic improvement at last-observation end point (SMD, -0.84; P = 0.02; I = 89%). Improvement with ECT separated from AP as early as weeks 1 to 2 (SMD, -1.26; P = 0.01; I = 89%). Meta-analysis of the end point memory quotient of the Wechsler Memory Scale-Revised, Chinese version, revealed that the ECT alone group had poorer memory performance than the AP group (WMD, -9.34; P < 0.00001; I = 0%), but the difference lost its significance within 2 weeks after ECT (WMD, 0.09 to -6.54; P = 0.11-0.97; I = 0%). Compared with AP monotherapy, ECT was associated with more memory impairment (OR, 14.11; P = 0.004; NNH, 6) but with less akathisia (OR, 0.06; P = 0.0009; NNH, 6), tremor (OR, 0.08; P = 0.02; NNH, 7), and tachycardia (OR, 0.06; P = 0.006; NNH, 5). There were no significant differences in other adverse events and all-cause discontinuation.

CONCLUSIONS:

Electroconvulsive therapy alone could be an effective and safe treatment option for schizophrenia, with transient memory impairment and headache being the major side effects.
Buscar no Google
Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Systematic_reviews Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Systematic_reviews Idioma: En Ano de publicação: 2016 Tipo de documento: Article